Herpes simplex virus (HSV) has two phases of its life cycle: lytic and latent infections (46). Lytic infection is characterized by the expression of all viral genes in a specific cascade (immediate-early, early, and late), leading to the production of infectious virus (34). During latent infection, viral gene expression is limited primarily to the latency-associated transcripts, with no infectious virus produced (50). When latently infected neurons are stressed, neurons become permissive for HSV lytic gene expression, leading to the production of infectious virions and the recurrence of diseases, such as those that cause cold sores, herpes keratitis, and encephalitis. A major player in facilitating the switch between lytic and latent infections in the HSV life cycle is the immediate-early regulatory protein, infected cell protein 0 (ICP0).
Herpes simplex virus (HSV) has two phases of its life cycle: lytic and latent infections (46) . Lytic infection is characterized by the expression of all viral genes in a specific cascade (immediate-early, early, and late), leading to the production of infectious virus (34) . During latent infection, viral gene expression is limited primarily to the latency-associated transcripts, with no infectious virus produced (50) . When latently infected neurons are stressed, neurons become permissive for HSV lytic gene expression, leading to the production of infectious virions and the recurrence of diseases, such as those that cause cold sores, herpes keratitis, and encephalitis. A major player in facilitating the switch between lytic and latent infections in the HSV life cycle is the immediate-early regulatory protein, infected cell protein 0 (ICP0).
ICP0 is a multifunctional, phosphorylated nuclear protein that acts as a transactivator of all three classes of HSV genes. This transactivating capability is required to induce efficient lytic gene expression and consequently efficient viral replication (9, 11, 14, 20, 21, 24, 31, 45, 51) . Moreover, ICP0 is also required for the efficient reactivation of quiescent viral genomes from latency (8, 32, 33, 35, 51, 55) . Taken together, these data indicate that ICP0 plays a critical role in both the initiation of lytic replication and the reactivation of latent viral genomes. The activation of viral gene expression by ICP0 is closely associated with its capacity to disrupt nuclear domain 10 (ND10) structures (also known as protein promyelocytic leukemia [PML] nuclear bodies) (37, 38) . These nuclear substructures are involved in modulating many cellular processes including proliferation, differentiation, and innate immunity (reviewed in references 25 and 42) . The disruption of ND10 occurs through ICP0-directed degradation of PML (the tumor suppressor protein, which is required for ND10 assembly) and, either directly or indirectly, the isoforms of Sp100 that are modified by the small ubiquitin-like modifier (13, 26, 41) . In order for ICP0 to target these and a number of other cellular proteins for proteasome-dependent degradation, it requires its zinc-binding RING finger domain, a motif that confers E3 ubiquitin ligase activity to ICP0 (7) . Ubiquitin ligases provide the substrate specificity required to mediate the transfer of ubiquitin from their respective ubiquitin-conjugating enzymes onto the substrate proteins targeted for modification (for a review, see reference 30). The ability of ICP0 to target specific cellular proteins for ubiquitination and proteasome-dependent degradation has given rise to the hypothesis that ICP0 counteracts the cellular repression mechanism(s) that either initiates or maintains viral genomes in a state of transcriptional quiescence.
As a number of E3 ubiquitin ligases have been shown to be regulated by phosphorylation, we wanted initially to determine the role ICP0 phosphorylation plays in its function. Specifically, we investigated whether phosphorylation affected its E3 ubiquitin ligase activity. Previously, we identified three regions of ICP0 phosphorylation by tandem mass spectrometry and determined by site-directed mutagenesis that two of the three phosphorylated regions were required for maximal ICP0 transactivating activity (16) . In the present study, we sought to establish whether the basis of these transactivation defects was coupled to changes in the ability of ICP0 to conjugate ubiquitin, dissociate ND10-associated proteins, and affect the stability of ICP0, phenotypes that are all dependent upon the E3 ubiquitin ligase activity of ICP0. Equivalent mutations were introduced into the HSV genome and virus isolates, and their revertants were characterized in cell culture. Our data indicate that although the mutations do not affect ICP0's E3 ligase activity in vitro, in transfected cells and in the absence of additional viral factors, two out of the three phosphorylation site (Phos) mutant forms of ICP0 potentially contribute to its E3 ubiquitin ligase activity in a cell type-dependent manner. However, only one ICP0 Phos mutant virus showed any significant reduction in replication relative to wild-type (wt) HSV in cell culture. Our results suggest that the context of expression of ICP0 and cell type may be important in the requirement for phosphorylation to regulate ICP0's ubiquitin ligase activity.
MATERIALS AND METHODS

Cells and viruses.
Vero, HEp-2, U2-OS, and HeLa cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA) and passaged as described previously (5, 48) . Human fetal foreskin fibroblast cells (HFFF-2), obtained from the European Collection of Cell Cultures, were grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 1% glutamine, and antibiotics. L7 cells, a Vero cell line stably transfected with the HSV-1 ICP0 gene, were cultured as described by Samaniego et al. (47) and used to titer all ICP0 mutant viruses described below. The wt HSV-1, strain KOS (passage 11), and 7134, an ICP0 null mutant, were propagated as previously described (11, 48) .
Transfection and immunofluorescence assays. Transfection of plasmid DNA was carried out using ExGen500 (Fermentas), following the manufacturer's instructions. Immunofluorescence was carried out as previously described (6), using the appropriate combinations of monoclonal anti-ICP0 (11060), anti-ubiquitin (BioMol [FK2 PW8810]) and rabbit anti-ICP0 (r191), and anti-PML (r8) and anti-Sp100 (SpGH) antibodies.
Immunoprecipitation, in vitro ubiquitin ligase assay, and Western blot analysis. HEp-2 cells (1 ϫ 10 6 cells) were transfected with 500 ng of the appropriate combination of plasmids expressing ICP0 and ICP0 Phos mutants. Sixteen hours posttransfection, the cells were washed and harvested in phosphate-buffered saline. Cell pellets were resuspended in 5 ml of buffer A (50 mM Tris [pH 8], 500 mM NaCl, 1% NP-40, 0.1% sodium deoxycholate, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol) supplemented with protease inhibitors (Roche Applied Sciences) and lysed by gentle bath sonication prior to incubation on ice for 30 min. Extracts were clarified by centrifugation (13,000 rpm for 15 min at 4°C) and precleared by tumbling with 50 l (50%, wt/vol) of equilibrated glutathione-Stransferase beads for 45 min at 4°C. ICP0 was immunoprecipitated using 1 g of ICP0 monoclonal anti-sera 11060 and 30 l (50%, wt/vol) of equilibrated protein G Sepharose for 2 h at 4°C. The beads were washed in buffer A (three times in 1 ml) and in buffer B (50 mM Tris [pH 8], 250 mM NaCl, 5 mM MgCl 2 , 0.1% NP-40, 1 mM dithiothreitol) (three times in 1 ml) and resuspended in a final volume of 30 l in buffer B. In vitro ubiquitin ligase reactions were carried out as previously described (7) using 15 l of immunoprecipitated bead extract for 90 min at 32°C. Reaction mixtures were analyzed by Western blot analysis for the presence of polyubiquitin conjugates using a monoclonal anti-ubiquitin antibody (P4D1; Santa Cruz Biotechnology). Western blot analyses for ICP0 were performed as previously described, using anti-ICP0 monoclonal antibody 11060 (6) .
Construction of ICP0 Phos mutants. HSV mutants carrying mutations in the major ICP0 phosphorylation sites (in the strain KOS background) were created by marker transfer, into the ICP0 null mutant virus 7134, essentially as described previously (11) . One microgram of 7134 infectious viral DNA was cotransfected with 2.5 g of each linearized Phos mutant plasmid in Vero cells (16) . Three to 7 days posttransfection, cells were harvested, frozen, and lysed, and samples were plated on Vero cells overlaid with Dulbecco's modified Eagle's medium containing 2% methylcellulose, X-Gal (5-bromo-4-chloro-3-inodyl-␤-D-glucuronic acid; 300 g/ml), and neutral red. Mutant viruses were identified as clear plaques, and each of these plaques was picked into 24-well plates. Viral DNAs from plaque picks were isolated, and incorporation of each Phos mutation into the viral genome was confirmed by Southern blot analyses using restriction enzyme digests (see Fig. 6 ). Positive isolates were plaque purified at least three times to create the viral Phos mutants, Phos 1 (P1), Phos 2 (P2), and Phos 3 (P3). To generate the marker rescue (MR) viruses, 1 g of P1, P2, or P3 viral DNA was cotransfected with 2.5 g of linearized pAlter-1ϩICP0 into Vero cells (16 
RESULTS
Characterization of the effects of ICP0 Phos mutations on ubiquitin conjugation in vitro and in cell culture. In a previous study, we identified two regions of ICP0 phosphorylation that were required for its maximal transactivating activity in transfection reporter assays (16) . Additional studies have indicated that ICP0's transactivating activity is dependent upon its RING finger E3 ubiquitin ligase activity. Mutations or deletions within the RING finger domain of ICP0 not only compromise its ability to conjugate ubiquitin but also greatly reduce its capability to act as a viral transactivator in reporter assays and significantly impair viral replication (7, (19) (20) (21) (22) (23) . E3 ubiquitin ligases provide the substrate specificity to catalyze the formation of ubiquitin chains on target proteins, typically directing them to the 26S proteasome for degradation. As ICP0 has previously been shown to induce the colocalization of conjugated ubiquitin in cell culture, a phenotype that is dependent on its RING finger domain (23), we initially wanted to examine the capacities of ICP0 Phos mutations to form conjugated ubiquitin chains both in cell culture and in vitro.
HEp-2 cells (a human larynx carcinoma cell line) were transfected with plasmids that expressed wt ICP0 and the mutants P1, P2, and P3 ( Fig. 1) , and immunofluorescence assays were performed by staining with an antibody that recognizes conjugated ubiquitin. As shown in Fig. 2A , cells expressing wt ICP0 efficiently induced the formation of colocalizing conjugated ubiquitin. However, such conjugated ubiquitin was not detected in P1-expressing cells ( Fig. 2A) , whereas P2 and P3 induced the conjugation of ubiquitin ( Fig. 2A) . Thus, one or more residues in the region of P1 are required for ICP0 to polymerize ubiquitin chains efficiently in HEp-2 cells. In order to determine whether residues mutated within P1 indirectly affected the folding of the RING finger domain or its ability to interact with its associated E2 ubiquitin-conjugating enzyme(s), HEp-2 cells were transfected with wt and mutant ICP0 expression plasmids. ICP0 proteins were immunoprecipitated from these cells and assayed for their abilities to catalyze the formation of polyubiquitin chains in vitro. As shown in Fig.  2B , all Phos mutants efficiently catalyzed the formation of polyubiquitin, indicating that these phosphorylation site residues are not required for the intrinsic E3 ubiquitin ligase activity of ICP0 in vitro. These data are consistent with previously published results, which demonstrated that only the first 211 amino acids of ICP0 are required for efficient E3 ligase activity in vitro (7). Thus, P1 has a functional RING domain with similar in vitro activity to that of wt ICP0.
P1 and P2 mutant forms of ICP0 are impaired in their abilities to disperse one or more proteins associated with ND10 structures. Given that at least one of the Phos mutants is altered in its ability to conjugate ubiquitin in cell culture, the next question we asked is whether this result correlates with an inability to disperse two ND10-associated proteins, PML and Sp100, in HEp-2 cells. Transfected cells were monitored for PML and Sp100 staining in immunofluorescence assays. The wt ICP0 induced the dispersal of PML (Fig. 3A) ; however, PML fluorescence remained colocalized in P1-and P2-expressing cells (Fig. 3A) but not P3-expressing cells. For Sp100, wt ICP0 and P3 also showed reduced staining ( Fig. 3B) , whereas P1-expressing cells colocalized with Sp100 (Fig. 3B ). In contrast to PML, P2 was capable of dispersing Sp100, indicating that this mutant form of ICP0 differentially affects the dispersal of these two ND10 constituents in HEp-2 cells. Taken together, these data indicate that two of the three phosphorylation domains of ICP0 are required to dissociate at least one protein from ND10.
The ubiquitin conjugation and PML dispersal activities of P1 are regulated in a cell type-specific manner. In addition to HEp-2 cells, the capacity of ICP0 to form ubiquitin chains was examined in Vero (African green monkey kidney) and HeLa (human cervical carcinoma) cells, two cell types that are commonly used to study ND10 structures and HSV replication. Employing the same experimental design described in the legend of Fig. 2A , the P1 expression vector was transfected into HEp-2, Vero, and HeLa cells. As shown in Fig. 4A , HEp-2 and a subset of HeLa cells that expressed P1 did not display detectable levels of conjugated ubiquitin colocalizing with ICP0. On the other hand, Vero and a subset of HeLa cells exhibited conjugated ubiquitin that colocalized with ICP0 mutant P1. When the Phos mutant forms of ICP0 were examined for PML staining in Vero cells (Fig. 4B) , wt ICP0, P1, and P3 were capable of dissociating PML from ND10, and a proportion of cells expressing P2 showed limited colocalization with PML. This latter result had been observed in a previously published study (16) . Thus, the E3 ubiquitin ligase activity of the Phos mutants (as measured by the production of colocalizing conjugated ubiquitin) correlates with their abilities to disperse PML, and these activities of P1 and P2 are modulated by their cellular environment in the absence of other viral proteins. These results also indicate that mutations in P1 and P2 appear not to indirectly alter the structure of ICP0 because their phenotypes in these assays are cell type specific.
P1 stability is increased in HEp-2 and HeLa cells. ICP0 RING finger mutants, which are deficient in their abilities to catalyze polyubiquitin formation, disrupt ND10, and transactivate HSV-1 gene expression, have an increased protein halflife in cell culture due to their inabilities to induce their own ubiquitination (7, 12, 19, 21-23, 26, 36) . Because two of the three Phos mutant proteins were impaired in at least two of (Fig. 2A) . A similar trend was noted with P1 in HeLa cells, although wt ICP0 stability was reduced in this cell type compared to that in HEp-2 cells. In contrast to these observations, wt ICP0 and the Phos mutants showed the same degree of stability in Vero cells following CHX treatment, indicating that the half-life of ICP0 is greater in Vero cells than in HeLa or HEp-2 cells. These tests indicate that P1 is more stable than wt ICP0, P2, and P3 in the two cell types that show a reduction in its E3 ubiquitin ligase activity and that ICP0 stability is dependent upon the cell type in which it is examined. Construction of viruses expressing ICP0 Phos mutants. In order to determine the role that ICP0 phosphorylation plays during lytic infection, the Phos mutations in each of the three regions of ICP0 (Fig. 1A and B) were introduced into the HSV-1 (strain KOS) genome by marker transfer, using the ICP0 null mutant virus 7134 as the parent. This mutant contains copies of the Escherichia coli lacZ gene in place of both copies of ICP0 coding sequence, under the control of the ICP0 promoter. Phos mutant viruses were identified as clear plaques in the presence of the ␤-galactosidase substrate, X-Gal. The resulting mutant viruses were designated P1, P2, and P3 for phosphorylation regions I, II, and III. Corresponding MR viruses of these mutants, termed P1MR, P2MR, and P3MR, were generated to ensure that any phenotypes observed with these mutants were not due to secondary mutations at other sites in the viral genome. Restriction enzyme digestions and Southern blot analyses were performed with wt HSV-1 (strain KOS), the Phos mutants, and MR virus DNAs (Fig. 6) to confirm mutation and repair of the ICP0 gene. The resulting viruses were then tested in several cell types to ascertain the impact of the Phos mutations on viral replication.
Replication of Phos mutants. (i) De novo virus synthesis from infectious viral DNA. HSV genomic DNA is infectious when transfected into many cell types, and previous studies have demonstrated that ICP0 significantly enhances the production of new viral particles as part of this process. To determine the extent to which the Phos mutations altered de novo viral particle synthesis relative to the other activities examined for the Phos mutants, viral DNAs from wt HSV-1 (strain KOS), ICP0 null mutant (7134), and the Phos mutants were transfected in Vero and HeLa cells. It was not possible to use HEp-2 cells in these experiments because of their poor trans- FIG. 3 . Mutation of residues within P1 and P2 prevents the dissociation of PML and/or Sp100 from ND10 in HEp-2 cells. HEp-2 cells were transfected with plasmids expressing either wt or Phos mutant (P1 to P3) forms of ICP0. Sixteen hours posttransfection, the cells were processed for confocal microscopy and stained with the ICP0 monoclonal antibody 11060 (shown in green) and rabbit anti-sera against either PML (r8) (A) or Sp100 (SpGH) (B) (both shown in red). Merged images show the colocalization of ICP0 with either PML (A) or Sp100 (B), respectively. White arrows highlight cells that express mutant ICP0 that failed to dissociate either PML or Sp100.
fection efficiency with viral genomic DNA. Vero and HeLa cells were harvested 2 and 3 days posttransfection, respectively, and plaque assays were performed to determine viral titers. Table 1 shows the results obtained from these studies. Transfection of wt KOS DNA gave virus yields of titer Ͼ10 6 PFU/ml in Vero cells and between 10 3 and 10 4 PFU/ml in HeLa cells. In contrast to KOS, the yield of 7134 was reduced as much as 4 orders of magnitude in Vero cells and ϳ2 orders of magnitude in HeLa cells. P1 titers were reduced 363-fold in Vero cells and 154-fold in HeLa cells. Interestingly, the yields of P1 were comparable to those of the ICP0-null mutant 7134 in HeLa cells. P2 and P3 titers were marginally reduced relative to those of KOS in both cell types. The replication of P1 was not complemented in Vero cells by cotransfecting a wt ICP0-expressing plasmid, which suggests that P1 may act as a dominant-negative mutant on wt ICP0 in this cell type (data not shown). Thus, mutations in P1 affected de novo viral replication in two cell lines, with the most deleterious effect observed in HeLa cells.
(ii) Replication and plating efficiencies of Phos mutants. Because of the difficulty in performing infectious viral DNA and plaque assays in HEp-2 cells to assess the role of ICP0 phosphorylation in lytic infection, we performed replication assays in Vero, HEp-2, and HeLa cells. Cells were infected at an MOI of 0.1 with KOS, 7134, the Phos mutants, and their Table 2 , KOS replicated to high levels in all three cell types. Relative to titers of KOS, titers of the 7134 mutant were impaired 2.4 logs in Vero cells and ϳ1 log in HeLa cells but were similar to those of KOS in HEp-2 cells. Of the Phos mutants, P1 was the only virus to show a slight growth deficiency (ϳ1.2 logs; 16-fold) in Vero and HeLa cells, with a less-marked reduction (ϳ1 log) in HEp-2 cells. Viral production for P2, P3, and the marker rescuants were comparable to or marginally reduced (Յ1 log) relative to KOS in the three cell lines examined.
Plaque formation of the Phos mutants was subsequently tested in U2-OS cells, a cell line in which ICP0 is not required for efficient HSV replication (53) , and HFFF-2 cells, a primary nontransformed human cell line in which the requirement of ICP0 to stimulate virus replication is critical (28) . Results from this study are shown in Table 3 . The efficiencies of plating of P1MR, P2, P2MR, P3, and P3MR between U2-OS and HFFF-2 cells were similar to KOS, ranging from 1.6-to 4.4-fold. Notably, plaque formation by P1 was reduced 20-fold in HFFF-2 compared to that in U2-OS cells, which is an approximately fivefold further decrease compared to KOS. Thus, one or more of the putative phosphorylated residues in phosphorylation region I are important for fully efficient plaque formation of HSV-1 in HFFF-2 cells.
Ubiquitin-conjugating and ND10-disrupting activities of the Phos mutants in HEp-2 cells. The Phos mutant viruses were then examined for ICP0's E3 ubiquitin ligase-associated activities in HEp-2 cells, given the results obtained in our transient assays with this cell line (Fig. 3 to 5 ). HEp-2 cells were infected with KOS or P1-P3 mutant viruses for 7 h, and the infected cells were assayed for their abilities to conjugate ubiquitin, disrupt the ND10-associated proteins PML and Sp100, and decrease PML levels. In contrast to the results in transfected cells presented earlier, wt ICP0 and the P1, P2, and P3 mutant forms all colocalized with conjugated ubiquitin (Fig. 7A ) and 
21.7
a Vero and HeLa cells were transfected with 0.125 g of viral DNA per well in a 12-well plate. Cells were harvested 48 h and 72 h posttransfection for Vero and HeLa cells, respectively. Experiments for these studies were done in duplicate and were repeated twice. 2 indicates a decrease in viral titers.
b Viral titers for KOS were determined on Vero cells, and viral titers for 7134 P1, P2, and P3 were determined on L7 cells. Similar viral titers were obtained from a second independent viral DNA preparation of P1 in these experiments. Additional transfection studies in U2-OS cells, an ICP0-complementing cell line, showed that P1 viral DNA was of comparable quality to KOS and 7134 viral DNAs (data not shown). a Cells were infected at an MOI of 0.1 for 1 h. Twenty-four hours postinfection, cells were harvested. Viral titers for KOS and MR viruses were determined on Vero cells and viral titers for 7134, P1, P2, and P3 were determined on L7 cells. Values in parentheses are the standard errors of the means. dispersed PML (Fig. 7B) and Sp100 (Fig. 7C ) from ND10. PML degradation was also observed in Hep-2 cells infected with KOS, P1, P2, P3, and their MR derivatives (data not shown). These results indicate that the phosphorylation sites in regions I, II, and III (Fig. 1 ) appear not to be required for these activities of ICP0 during lytic viral replication in HEp-2 cells.
P1 has greater stability in HFFF-2 cells during viral replication. ICP0 mutants with increased protein stabilities have been shown to be impaired for viral replication (5, 12, 36) . Because P1 showed greater stability in transient transfection assays and replicated at reduced levels in primary HFFF-2 cells, we then wanted to examine the stabilities of the Phos mutant forms of ICP0 relative to those of wt ICP0 in HFFF-2 during viral infection. For these experiments, cells were infected with 2 PFU of wt, mutant, and MR viruses per cell. Four hours postinfection, CHX was added to cells to block de novo Fig. 8 . P1 was considerably more stable than wt protein (expressed from wt or MR viruses), P2, and P3, indicating that a decrease in protein turnover for P1 correlates with a decrease in viral replication in HFFF-2 cells.
DISCUSSION
The ability of ICP0 to target specific cellular proteins for ubiquitination and proteasome-dependent degradation is thought to be crucial for promoting high levels of viral gene expression, replication, and reactivation. While it has long been established that ICP0 undergoes phosphorylation during infection (2, 3, 15, 52) , little is known as to how these phosphorylation events specifically regulate the biological functions of ICP0 (3, 4, 16, 17, 43) . In this study we initially sought to determine whether ICP0 phosphorylation modulated its E3 ubiquitin ligase activity and its associated ability to induce the dispersal and degradation of PML and Sp100 from ND10. Our results bring to light new complexities in trying to understand the biological phenotypes of this important regulatory protein.
Although the Phos mutations did not affect ICP0's E3 ubiquitin ligase activity in vitro, cell-based transfection assays in the absence of other viral factors showed that mutation of two out of the three phosphorylated regions inhibited the ability of ICP0 to form conjugated ubiquitin chains (Fig. 2, row 2 ) and to dissociate PML (Fig. 3, rows 2 and 3) and Sp100 (Fig. 4B, row  2 ) from ND10 structures. Moreover, the reduced ubiquitin conjugation activity of P1 in transfected HEp-2 and a portion of HeLa cells directly correlates with an increase in its protein stability compared to either wt ICP0 or P2 and P3 mutants in the two cell types. These results are consistent with previous data that demonstrate that ICP0 mutants with reduced E3 ligase function have increased stabilities due to decreased auto-ubiquitination activity and therefore increased half-life (5, 12) . Thus, this study is the first direct evidence to suggest a potential mechanism as to how phosphorylation may regulate this activity of ICP0. In direct contrast to HEp-2 and HeLa cells, however, expression of P1 in Vero cells promoted ubiquitin conjugation and dissociation of PML from ND10 structures. This apparent difference in ICP0 E3 ubiquitin ligase activity between cell types does not correlate with a decrease in protein stability. In actuality, expression of wt ICP0 in Vero cells shows a significant increase in protein stability compared to that of either HEp-2 or HeLa cells. Because the P1 and P2 mutants have cell type-specific activities in our assays and are active in vitro, we can conclude that the overall structure of ICP0 appears not to be affected in these mutant forms of ICP0. Collectively, our data highlight the complex enzymatic properties of ICP0 using transient transfection approaches in cell culture.
When these mutations were introduced into the HSV-1 genome, only P1 was noticeably diminished for viral replication following transfection of infectious viral DNA into HeLa cells and exhibited reduced plaque formation in HFFF-2 cells. Furthermore, only P1 showed enhanced ICP0 stability, similar to results observed in HeLa and HEp-2 cells in transient expression assays. In contrast to our infectious viral DNA studies, P1 mutations in the context of an infectious virus had only a slight impact on productive replication in Vero, HeLa, or HEp-2 cells. This minor effect of P1 on viral replication is likely compensated by higher levels of ICP0 expression and/or the presence of other viral transactivators, for example, VP16 and ICP4, aiding the virus to initiate lytic replication in these three cell types (1, 40, 49) . Analysis of the P1 mutant in HFFF-2 cells, a primary human fibroblast cell line, demonstrated a small but reproducible impairment in viral replication, which correlated with a decrease in P1 turnover (Fig. 8) . Taken together, this study suggests that specific cellular environments and context of expression (transfection versus infection) may differentially affect the influence of phosphorylation on several activities related to ICP0-directed ubiquitination.
Role of P1 sites in ICP0 function. The RING finger of ICP0 and regions adjacent to it have been shown to be important for ICP0 to induce the conjugation of ubiquitin and activate viral gene expression (7, 20, 21) . Because mutations in P1 impair the E3 ubiquitin ligase activity (in cultured cells if not in vitro) and lie near the RING finger of ICP0, our data provide further support of the ancillary function these adjoining domains have on the E3 ubiquitin activity of ICP0. Furthermore, these observations suggest that phosphorylation can regulate this process. Because phosphorylation has been reported to control the auto-ubiquitination and/or degradation of the E3 ubiquitin ligases MDM2, Cbl, and COP1 (18, 29, 39, 54) , our results with P1 suggest that this may also be the case for ICP0. The decreased ability of P1 to catalyze the formation of ubiquitin chains and the associated increase in protein stability suggest that in restrictive cells, inhibition of ICP0 phosphorylation in region I potentially hinders its interactions with cofactors required for its E3 ubiquitin ligase activity, auto-ubiquitination, and consequently its ability to be targeted for proteolysis. Alternatively, the mutations made within the P1 motif might compromise the E3 ubiquitin ligase activity of ICP0 in intracellular contexts, with the same consequences.
One such interaction that may be affected is that of ICP0's interaction with USP7. This protein, a ubiquitin-specific protease, removes ubiquitin from target proteins, including E3 ubiquitin ligases, promoting their stabilization. A complicating issue is that wt ICP0 mediates the degradation of USP7 during HSV infection in Vero, HEp-2, and HeLa cells (5) . Viruses that do not contain the RING finger domain or cannot bind to USP7 are unable to degrade USP7 (5, 12) . If inhibition of ICP0-USP7 binding leads to reduced ICP0 protein stability, it is possible that enhanced ICP0-USP7 interactions (through increased USP7 stability and/or binding) upon inhibition of ICP0 phosphorylation could diminish its turnover. In support of this model, a link between the phosphorylation state of E3 ubiquitin ligases and USP7 binding has been made, as phosphorylation of MDM2 E3 ubiquitin ligase family members has been shown to reduce their affinity for USP7, destabilizing their protein levels (39) . Lastly, the activity of USP7 has been described to be cell type dependent, which may also contribute to the cell-specific phenotypes observed with P1 in our studies (44) .
P2 differentially affects the localization of two ND10-associated proteins. One striking result from our experiments is the modulation of ICP0 activities by mutation of the P2 region. Our transient assays in HEp-2 cells showed that P2 cannot dissociate PML from ND10 but is capable of dissociating Sp100. This mutant form of ICP0 can form polyubiquitin chains in HEp-2 cells, demonstrating that its E3 ubiquitin ligase activity appears to be intact, at least at this level of analysis. Notably, this is the first mutant form of ICP0 described that differentially affects the staining of two ND10-associated proteins. Our results indicate that in the absence of other viral factors in HEp-2 cells, the phosphoacceptor sites in region II of ICP0 play a role in dispersing or degrading PML but are not required for dispersal of Sp100. While initial results on the consequences of ICP0 expression on Sp100 expression and localization favored a model involving a direct effect of ICP0 on Sp100, more recent data suggest that depletion of PML either by ICP0 or by RNA interference leads to changes in Sp100 that are indistinguishable from those that occur during HSV infection. Thus, the differential effects of P2 on PML and Sp100 do not necessarily imply alterations in the substrate specificity of ICP0 by loss of potential phosphorylation (27) . It is equally possible that in HEp-2 cells the P2 mutant is unable to disperse/degrade PML, but nonetheless is able to affect PML in such a way that Sp100 is no longer stably associated with ND10.
The potential impact that the P2 mutations might have on HSV replication is not apparent in this study, as these lesions do not appreciably alter HSV growth or plaque formation in the cell types tested. The distinct phenotypes associated with P2 may only become evident when assaying for other activities of ICP0 or in another context (e.g., in vivo infection and reactivation experiments). Future work with the Phos mutants will ascertain which specific phosphorylation sites on ICP0 are required for selected activities of this multifunctional protein that is crucial for efficient HSV replication and reactivation.
